Video

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

IPI-145 is a potent oral inhibitor PI3K-delta and -gamma that was examined in a phase I trial that enrolled 44 patients with relapsed or refractory CLL. Overall, there was a 47% overall response rate, as evaluated by modified IWCLL criteria, in a heavily pretreated population of patients with CLL, Flinn notes. Additionally, there was a 50% response rate even in patients with 17p deletions or TP53 mutation.

When considering the mild toxicity profile along with the efficacy, IPI-145 represents a very promising new treatment option, Flinn notes. As a result, IPI-145 will be further examined in a phase III trial in comparison to ofatumumab.

<<<

View more from the 2013 ASH Annual Meeting

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity